- Existing-Home Sales Jump to 2-1/2 Year High
- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Late Payments on Credit Cards Drop in Third Quarter
- Suze Orman’s 'A Healthier, Wealthier You'
- Latest Holiday Drinks: The Madoff...and the TARPatini
- Madoff Trustee, Law Firm Submit $22.1 Million Bill
- JPMorgan's Dimon Could Succeed Geithner: Report
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Madoff—The Holiday Drink
- HP to Feed on Enterprise Spending Next Year: Tech Analyst
- Busch: Markets Smell a Country Rat
- Schork Oil Outlook: Mission Impossible For The Bears?
- S&P Stocks Trading at New 52-Week Highs
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Don't Dwell on Investment Mistakes; Move on, Like Buffett
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Start-Up Proves Everything Really Is Better With Bacon
- Wave of Debt Payments Facing US Government
- Wall Street Finds Profits by Reducing Mortgages
- Cadbury Hits New High as Bidders Circle
- China Asks Its Banks to Slow Down
- MBS Buyback Program Should be Extended: Fed's Bullard
Text Size 
The director of the FDA's division of antiviral products is urging caution in the use of a new flu drug that just won special permission to fight H1N1.
Two weeks ago the FDA gave Emergency Use Authorization for the IV drug peramivir from BioCryst Pharmaceuticals [BCRX
Loading...
()
].
The EUA allows doctors to ask the CDC for access to the drug for use only on certain hospitalized pediatric and adult patients.
But the FDA's Dr. Debra Birnkrant, in an Op-Ed piece in "The New England Journal of Medicine" writes, "Alternatives should be considered."
She points out that peramivir remains formally unapproved and adds, "No conclusions about efficacy can be drawn" from previous studies of peramivir on the seasonal flu.
"There are very limited data available regarding the use of peramivir in seriously ill hospitalized patients," Dr. Birnkrant writes.
Peramivir is the third flu-fighting drug available to combat H1N1, but is the only IV treatment. Roche [RHBBY
Loading...
()
] and Gilead Sciences [GILD
Loading...
()
] are behind the most popular remedy, Tamiflu. GlaxoSmithKline [GSK
Loading...
()
] makes the smaller-selling inhalable Relenza.
In an email, a BioCryst spokesman tells CNBC the NEJM article "should help improve awareness of peramivir and the EUA in the medical community. Hopefully, peramivir will reach a greater portion of hospitalized patients...." The company says it's prepared to deliver up to 130,000 courses of the drug by the end of this year.
Print
Email
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- A Macau casino will open Asia's first Michael Jackson shrine after its owners made a key purchase at a US auction.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes